Skip links

SciNeuro to Join Endpoints Roundtable at BIO 2023

Rockville, Maryland, USA and Shanghai, China. May 25, 2023 – SciNeuro Pharmaceuticals, a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, today announced that Dr. Min Li, Founder and Chief Executive Officer, will join John Carroll of Endpoints News at BIO 2023 on Wednesday, June 7, 2023 to discuss the future trends and global strategy in biopharma.

Please visit Endpoints at #BIO23 to join in person or register for virtual sessions.

About SciNeuro Pharmaceuticals
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases. To learn more, visit

SciNeuro Media Contact
Jessie Yang